KRAS and clear cell adenocarcinoma: Clinicopathologically, a dualistic model of ovarian cancer has been proposed: Type I tumors, comprised of low-grade serous, low-grade endometrioid, mucinous, and clear cell carcinomas, typically possess mutations in KRAS, PTEN, and CTNNB1 [40].